Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: A study by the Centers for AIDS Research Network of Integrated Clinical Systems

JAMA Cardiology

Volumn 2, Issue 2, 2017, Pages 155-162

  Feinstein, Matthew J ^a   Nance, Robin M ^b   Drozd, Daniel R ^b   Ning, Hongyan ^a   Delaney, Joseph A ^c   Heckbert, Susan R ^c   Budoff, Matthew J ^d   Mathews, William C ^e   Kitahata, Mari M ^b   Saag, Michael S ^f   Eron, Joseph J ^g   Moore, Richard D ^h   Achenbach, Chad J ^a   Lloyd Jones, Donald M ^a   Crane, Heidi M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UCSD MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BLACK PERSON; CALIBRATION; CARDIOVASCULAR RISK; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; NONHUMAN; POOLED COHORT EQUATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; RISK ESTIMATION MODEL; SEX DIFFERENCE; STATISTICAL CONCEPTS; VALIDATION PROCESS; VIRUS LOAD; CLINICAL TRIAL; COMPLICATION; FORECASTING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PROCEDURES; RISK FACTOR; UNITED STATES; VIROLOGY;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; VIRAL LOAD;

EID: 85015608880     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.4494     Document Type: Article

References (35)

1. Palella FJ Jr, Baker RK, Moorman AC, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1): 27-34.
2. Rodger AJ, Lodwick R, Schechter M, et al; INSIGHT SMART, ESPRIT Study Groups. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS. 2013; 27(6):973-979.
3. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293-299.
4. Sullivan PS, Jones JS, Baral SD. The global north: HIV epidemiology in high-income countries. Curr Opin HIV AIDS. 2014;9(2):199-205.
5. Hall HI, An Q, Tang T, et al; Centers for Disease Control and Prevention. Prevalence of diagnosed and undiagnosed HIV infection-United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64 (24):657-662.
6. World Health Organization. Global Health Observatory data. HIV/AIDS: global situation and trends. http://www.who.int/gho/hiv/en/. Accessed July 13, 2015.
7. Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271-276.
8. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
9. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-622.
10. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60(4): 351-358.
11. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205(suppl 3):S375-S382.
12. Feinstein MJ, Bahiru E, Achenbach C, et al. Patterns of cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol. 2016;117(2):214-220.
13. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171(8):737-743.
14. Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. 2012;59(21):1891-1896.
15. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
16. Currier JS, Lundgren JD, Carr A, et al; Working Group 2. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29-e35.
17. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr. 2010;55(5):615-619.
18. Moyers BS, Secemsky EA, Vittinghoff E, et al. Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus. Am J Cardiol. 2014; 113(7):1260-1265.
19. Shah MR, Cook N, Wong R, et al. Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease. J Am Coll Cardiol. 2015;65(7):738-744.
20. Aboud M, Elgalib A, Pomeroy L, et al. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 Study. Int J Clin Pract. 2010;64(9):1252-1259.
21. Edwards-Jackson N, Kerr S, Tieu H, et al; HIV-NAT 006 Study Team. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med. 2011;12 (8):510-515.
22. Moreira Guimarães MM, Bartolomeu Greco D, Ingles Garces AH, de Oliveira AR Jr, Bastos Fóscolo R, de Campos Machado LJ. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract. 2010;64 (6):739-745.
23. Friis-Møller N, Ryom L, Smith C, et al; D:A:D Study Group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214-223.
24. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25; pt B):2935-2959.
25. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, pt B):2889-2934.
26. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014; 311(14):1406-1415.
27. Crane HM, Heckbert SR, Drozd DR, et al; Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol. 2014;179(8): 996-1005.
28. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167-176.
29. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the third National Health and Nutrition Examination Survey. Circulation. 2001;103(4):502-506.
30. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121(15):1768-1777.
31. Demler OV, Paynter NP, Cook NR. Tests of calibration and goodness-of-fit in the survival setting. Stat Med. 2015;34(10):1659-1680.
32. Centers for Disease Control and Prevention. HIV in the United States: at a glance. http://www.cdc.gov/hiv/statistics/overview/ataglance.html. Updated July 11, 2016. Accessed May 4, 2016.
33. Thygesen K, Alpert JS, Jaffe AS, et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020-2035.
34. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol. 2015;115(12):1760-1766.
35. Amarenco P, Tonkin AM. Statins for stroke prevention: disappointment and hope. Circulation. 2004;109(23)(suppl 1):III44-III49.